IFP Advisors’s Corbus Pharmaceuticals CRBP Stock Holding History

IFP Advisors’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-5,897	Closed	-$1.46M	–	4092
2017 Q1	$1.46M	Buy	+5,897	New	+$1.45M	0.06%	326

Other funds holding CRBP

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

IFP Advisors's CRBP Position: Q4 2025 in Review

IFP Advisors sold out of Corbus Pharmaceuticals (CRBP) in Q4 2025, closing a stake of 19 shares — an estimated $240 sold.

IFP Advisors first reported a position in CRBP in Q1 2016 and held it in 31 quarters. The position peaked at $11.4M in Q3 2018. 100 funds tracked by Wall St. Rank hold CRBP as of Q4 2025.

IFP Advisors reported no remaining Corbus Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
IFP Advisors sold 19 Corbus Pharmaceuticals shares in Q4 2025, an estimated $240.
IFP Advisors first reported a position in Corbus Pharmaceuticals in Q1 2016 and held it in 31 quarters.
IFP Advisors's Corbus Pharmaceuticals position peaked at $11.4M in Q3 2018.
100 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q4 2025.

Based on IFP Advisors's 13F filing for Q4 2025, filed 6 Feb 2026.